Showing results (21-30 of 969) with videos related to
Sort By:
Pageof 97
Leukemia & Lymphoma|May 22, 2014
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromesElias Jabbour, Guillermo Garcia-Manero, A Megan Cornelison, et al.Blood Advances|January 4, 2018
Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML groupPrajwal Boddu, Hagop Kantarjian, Gautam Borthakur, et al.Advances in Experimental Medicine and Biology|January 1, 2022
An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!Fadi Haddad, Naval DaverThe American Journal of Managed Care|August 23, 2018
Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemiaMegan Wiese, Naval DaverDrugs|June 22, 2019
From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid LeukemiaMusa Yilmaz, Naval DaverHematology (Amsterdam, Netherlands)|April 18, 2012
Molecular targeted therapy in acute myeloid leukemiaNaval Daver, Jorge CortesLeukemia & Lymphoma|May 25, 2019
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapyPrajwal Boddu, Preetesh Jain, Gautam Borthakur, et al.Leukemia & Lymphoma|August 15, 2014
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxideAlireza Eghtedar, Ildefonso Rodriguez, Hagop Kantarjian, et al.Current Hematologic Malignancy Reports|March 30, 2013
Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodiesNaval Daver, Susan O'BrienThe American Journal of Managed Care|August 23, 2018
Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathwayLindsey Lyle, Naval DaverPageof 97